IMB 2024 Financial Report: Profit Up 4.5%, NGP Revenue Jumps 26%

Nov.19.2024
IMB 2024 Financial Report: Profit Up 4.5%, NGP Revenue Jumps 26%
Imperial Brands released its full-year 2024 financial results, reporting a 0.2% year-on-year decline in total revenue to £32.411 billion, while adjusted operating profit increased by 4.5% year-on-year to £3.887 billion.

On November 19, Imperial Brands (IMB) announced its full-year financial results for the period ending September 30, 2024. The company reported a slight decline in total revenue, which fell by 0.2% year-on-year to £32.411 billion.

 

Despite the dip in revenue, adjusted operating profit rose by 4.5% to £3.887 billion. Adjusted net revenue for the "Tobacco and Next Generation Products (NGP)" segment increased by 4.6%, reaching £8.157 billion.

 

Key highlights of the report:

 

  • Tobacco and NGP net revenue increased by 4.6%.
  • Market share gains were reported in four out of IMB’s five priority markets, with an overall increase of 0.05%.
  • NGP's net revenue grew by 26%, with all three regions achieving growth and improved margins.
  • Logista's growth reflected strong tobacco pricing and benefits from last year’s acquisitions.
  • Adjusted earnings per share (EPS) rose by 10.9%, driven by profit growth and a reduced share count, while reported EPS increased by 19.1%.
  • Strong cash generation, with free cash flow reaching £2.4 billion.
  • IMB plans to return approximately £2.8 billion to shareholders in FY25, including a £1.25 billion share buyback and a 4.5% increase in the FY24 dividend.

 

IMB 2024 Financial Report: Profit Up 4.5%, NGP Revenue Jumps 26%
IMB Full-Year Report to September 30, 2024| Source: IMB official website

 

The report highlights that overall market share in IMB’s five priority markets increased by 5 basis points (bps). Growth was recorded in the U.S., Germany, Spain, and Australia, while the U.K. saw a decline.

 

In Europe, strong growth in tobacco and Next Generation Product (NGP) net revenue was noted, with a stable market share in Germany. In the Americas, the successful launch of the modern oral nicotine brand "Zone" drove a 29.4% increase in NGP net revenue. In Africa, Asia, and the Middle East, effective tobacco pricing strategies contributed to further market share expansion.

 

Notably, NGP's net revenue grew by 26.4%, with all three categories—heated tobacco, vaping, and modern oral —experiencing growth.

 

Stefan Bomhard, CEO of IMB, said:


"As we enter the final year of our current strategy, the investment we have made in consumer capabilities, cultural transformation and agile ways of working has supported another year of accelerated financial delivery and growing capital returns. "

 

"In tobacco, investment in our brands and sales force initiatives have delivered aggregate market share gains across our five priority markets, while delivering strong pricing. This was supported by an encouraging stabilisation in German market share for the first time under our strategy"

 

"In next generation products (NGP), we continue to build scale across our footprint with net revenues up 26.4% at constant currency driven by growth from all three regions and market share growth in all three categories. Our partnership approach to product innovation has enabled us to launch new products across all three categories during the year. This included our successful entry to the fast-growing modern oral category in the US with our brand ‘Zone’."

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Consultation opens for Tasmania’s Public Health Amendment Bill 2026
Consultation opens for Tasmania’s Public Health Amendment Bill 2026
Consultation opened on February 6, 2026 for the Public Health Amendment (Prohibited Tobacco and Other Products) Bill 2026. The Bill intends to address illicit trade in tobacco, nicotine pouches and e-cigarettes, which has increased significantly across Tasmania in recent years. It proposes changes to the Public Health Act 1997 to further protect the health of Tasmanians by reducing the sale and supply of illicit tobacco, vaping and other products, and to strengthen existing tobacco control laws.
Feb.06 by 2FIRSTS.ai
Belgium Calls for EU-Wide Limits on Vape Ingredients and Ban on Disposable E-Cigarettes
Belgium Calls for EU-Wide Limits on Vape Ingredients and Ban on Disposable E-Cigarettes
Belgian Health Minister Frank Vandenbroucke has called on the European Union to take stronger action on vaping, saying it is becoming an “epidemic” and accusing the industry of targeting young people.
Mar.26 by 2FIRSTS.ai
Myanmar announces ban on e-cigarettes, covering imports/exports, sales, possession and use
Myanmar announces ban on e-cigarettes, covering imports/exports, sales, possession and use
Myanmar’s Ministry of Health said it has received cabinet authorization to enforce an e-cigarette ban under the Essential Supplies and Services Law, listing prohibited acts including the import, export, sale, possession, storage, carrying, distribution and use of vaping products.
Feb.26 by 2FIRSTS.ai
Alaska AG warns 1,500+ retailers to stop selling unauthorized vapes and nicotine pouches
Alaska AG warns 1,500+ retailers to stop selling unauthorized vapes and nicotine pouches
Alaska’s attorney general has sent warning letters to more than 1,500 retailers and distributors, cautioning them against selling tobacco products — including e-cigarettes and oral nicotine pouches — that lack U.S. Food and Drug Administration authorization.
Mar.06 by 2FIRSTS.ai
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
A patent published on February 24, 2026, by China Tobacco Hubei Industrial Co., Ltd. introduces a “nicotine jelly” product designed to combine rapid and sustained nicotine delivery. By integrating both free and microencapsulated nicotine, the product aims to address key limitations of traditional nicotine replacement therapy (NRT), while also raising new regulatory and product classification questions.
Innovation
Mar.18
PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries
PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries
During FDA’s Feb 10 PMTA roundtable (manufacturing controls panel), small ENDS manufacturers warned that uncertainty in manufacturing expectations creates existential financial risk. FDA officials reiterated review flexibility is constrained by statutory and scientific boundaries. The panel debated testing standards, documentation requirements, open-system responsibility, supply chain changes, and software updates—highlighting unresolved PMTA challenges for small manufacturers.
Feb.11